{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:31:14Z","timestamp":1770741074093,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The lack of biomarkers for early diagnosis, clinical stratification and to monitor treatment response has hampered the development of new therapies for amyotrophic lateral sclerosis (ALS), a clinically heterogeneous neurodegenerative disorder with a variable site of disease initiation and rate of progression. To identify new biomarkers and therapeutic targets, two separate proteomic workflows were applied to study the immunological response and the plasma\/brain proteome in phenotypic variants of ALS. Conventional multiplex (TMT) proteomic analysis of peripheral blood mononuclear cells (PBMCs) was performed alongside a recently introduced method to profile neuronal-derived proteins in plasma using brain tissue-enhanced isobaric tagging (TMTcalibrator). The combined proteomic analysis allowed the detection of regulated proteins linked to ALS pathogenesis (RNA-binding protein FUS, superoxide dismutase Cu-Zn and neurofilaments light\u00a0polypeptide) alongside newly identified candidate biomarkers (myosin-9, fructose-bisphosphate aldolase and plectin). In line with the proteomic results, orthogonal immunodetection showed changes in neurofilaments and ApoE in bulbar versus limb onset fast progressing ALS. Functional analysis of significantly regulated features showed enrichment of pathways involved in regulation of the immune response, Rho family GTPases, semaphorin and integrin signalling. Our cross-phenotype investigation of PBMCs and plasma\/brain proteins provides a more sensitive biomarker exploratory platform than conventional case-control studies in a single matrix. The reported regulated proteins may represent novel biomarker candidates and potentially druggable targets.<\/jats:p>","DOI":"10.1038\/s41598-019-40632-4","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T12:06:06Z","timestamp":1552565166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis"],"prefix":"10.1038","volume":"9","author":[{"given":"Emanuela","family":"Leoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bremang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Zubiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-5089","authenticated-orcid":false,"given":"Ching-Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Adiutori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasa","family":"Koncarevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Pike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"40632_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/jnnp.2009.188151","volume":"9","author":"K Talbot","year":"2009","unstructured":"Talbot, K. Motor neuron disease: the bare essentials. Practical neurology. 9, 303\u20139 (2009).","journal-title":"Practical neurology."},{"key":"40632_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000351153","volume":"41","author":"A Chi\u00f2","year":"2013","unstructured":"Chi\u00f2, A. et al. Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology. 41, 118\u201330 (2013).","journal-title":"Neuroepidemiology."},{"key":"40632_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3109\/21678421.2014.990036","volume":"16","author":"H Watanabe","year":"2015","unstructured":"Watanabe, H. et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 16, 230\u2013236 (2015).","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"40632_CR4","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"C-H Lu","year":"2015","unstructured":"Lu, C.-H. et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 84, 2247\u201357 (2015).","journal-title":"Neurology."},{"key":"40632_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jneuroim.2009.02.012","volume":"210","author":"S Mantovani","year":"2009","unstructured":"Mantovani, S. et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol. 210, 73\u20139 (2009).","journal-title":"J Neuroimmunol."},{"key":"40632_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/emmm.201201544","volume":"5","author":"JS Henkel","year":"2013","unstructured":"Henkel, J. S. et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 5, 64\u201379 (2013).","journal-title":"EMBO Mol Med."},{"key":"40632_CR7","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1096\/fj.201600259RR","volume":"30","author":"L Lam","year":"2016","unstructured":"Lam, L. et al. Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients. FASEB J. 30, 3461\u201373 (2016).","journal-title":"FASEB J."},{"key":"40632_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12017-014-8321-y","volume":"16","author":"AC Ladd","year":"2014","unstructured":"Ladd, A. C., Keeney, P. M., Govind, M. M. & Bennett, J. P. Mitochondrial Oxidative Phosphorylation Transcriptome Alterations in Human Amyotrophic Lateral Sclerosis Spinal Cord and Blood. NeuroMolecular Med. 16, 714\u201326 (2014).","journal-title":"NeuroMolecular Med."},{"key":"40632_CR9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1126\/scitranslmed.aai7866","volume":"9","author":"TF Gendron","year":"2017","unstructured":"Gendron, T. F. et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 9, 383 (2017).","journal-title":"Sci Transl Med."},{"key":"40632_CR10","doi-asserted-by":"crossref","unstructured":"Kon\u010darevi\u0107, S. et al. In-Depth Profiling of the Peripheral Blood Mononuclear Cells Proteome for Clinical Blood Proteomics. Int J Proteomics. 129259 (2014).","DOI":"10.1155\/2014\/129259"},{"key":"40632_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neulet.2009.10.053","volume":"468","author":"J Brettschneider","year":"2010","unstructured":"Brettschneider, J. et al. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). J Neuroscience letters. 468, 23\u20137 (2010).","journal-title":"J Neuroscience letters."},{"key":"40632_CR12","doi-asserted-by":"publisher","first-page":"e79733","DOI":"10.1371\/journal.pone.0079733","volume":"8","author":"L Conraux","year":"2013","unstructured":"Conraux, L. et al. Plasma Peptide Biomarker Discovery for Amyotrophic Lateral Sclerosis by MALDI \u2013TOF Mass Spectrometry Profiling. PLoS One. 8, e79733 (2013).","journal-title":"PLoS One."},{"key":"40632_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/mus.21683","volume":"42","author":"H Ryberg","year":"2010","unstructured":"Ryberg, H. et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. J Muscle & nerve. 42, 104\u201311 (2010).","journal-title":"J Muscle & nerve."},{"key":"40632_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0589-4","volume":"13","author":"U Wormser","year":"2016","unstructured":"Wormser, U. et al. Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment. J Neuroinflammation. 13, 131 (2016).","journal-title":"J Neuroinflammation."},{"key":"40632_CR15","doi-asserted-by":"publisher","first-page":"e0171668","DOI":"10.1371\/journal.pone.0171668","volume":"12","author":"A Drannik","year":"2017","unstructured":"Drannik, A. et al. Cerebrospinal fluid from patients with amyotrophic lateral sclerosis inhibits sonic hedgehog function. PLoS One. 12, e0171668 (2017).","journal-title":"PLoS One."},{"key":"40632_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jprot.2014.05.004","volume":"108","author":"K Elf","year":"2014","unstructured":"Elf, K. et al. Alterations in muscle proteome of patients diagnosed with amyotrophic lateral sclerosis. J Proteomics. 108, 55\u201364 (2014).","journal-title":"J Proteomics."},{"key":"40632_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/rcm.7777","volume":"31","author":"C Russell","year":"2017","unstructured":"Russell, C. et al. Combined tissue and fluid proteomics with tandem mass tags to identify low-abundance protein biomarkers of disease in peripheral body fluids: an alyheimer\u2019s disease case study. Rapid Commun Mass spectrometry. 31, 153\u2013159 (2017).","journal-title":"Rapid Commun Mass spectrometry."},{"key":"40632_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13024-018-0292-2","volume":"13","author":"I Zubiri","year":"2018","unstructured":"Zubiri, I. et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 13, 60 (2018).","journal-title":"Mol Neurodegener."},{"key":"40632_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.24470","volume":"51","author":"MR Turner","year":"2015","unstructured":"Turner, M. R. & Benatar, M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 51, 14\u20138 (2015).","journal-title":"Muscle Nerve."},{"key":"40632_CR20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3988\/jcn.2015.11.4.376","volume":"11","author":"SI Oh","year":"2015","unstructured":"Oh, S. I. et al. Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. Journal of clinical neurology. 11, 376\u2013382 (2015).","journal-title":"Journal of clinical neurology."},{"key":"40632_CR21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2012.07.016","volume":"34","author":"A Chio","year":"2013","unstructured":"Chio, A. et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiology of aging. 34, 357 (2013).","journal-title":"Neurobiology of aging."},{"key":"40632_CR22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet. 377, 942\u2013955 (2011).","journal-title":"Lancet."},{"key":"40632_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00401-012-1039-8","volume":"125","author":"EA Winkler","year":"2013","unstructured":"Winkler, E. A. et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 125, 111\u2013120 (2013).","journal-title":"Acta Neuropathol."},{"key":"40632_CR24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11011-018-0239-x","volume":"33","author":"X Fang","year":"2018","unstructured":"Fang, X. Impaired tissue barriers as potential therapeutic targets for Parkinson\u2019s disease and amyotrophic lateral sclerosis. Metab Brain Dis. 33, 1031\u20131043 (2018).","journal-title":"Metab Brain Dis."},{"key":"40632_CR25","first-page":"8","volume":"23","author":"CA Mayer","year":"2013","unstructured":"Mayer, C. A. et al. Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases. PLoS One. 23, 8 (2013).","journal-title":"PLoS One."},{"key":"40632_CR26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1515\/cclm-2014-0908","volume":"53","author":"E Mart\u00ednez-Morillo","year":"2015","unstructured":"Mart\u00ednez-Morillo, E. et al. Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. Clin Chem Lab Med. 53, 1575\u201384 (2015).","journal-title":"Clin Chem Lab Med."},{"key":"40632_CR27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/intimm\/dxu099","volume":"27","author":"A Malaspina","year":"2014","unstructured":"Malaspina, A. et al. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol. 27, 117\u201329 (2014).","journal-title":"Int Immunol."},{"key":"40632_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fncel.2014.00314","volume":"8","author":"TR Stankiewicz","year":"2014","unstructured":"Stankiewicz, T. R. & Linseman, D. A. Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration. Front Cell Neurosci. 8, 314 (2014).","journal-title":"Front Cell Neurosci."},{"key":"40632_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fnagi.2017.00094","volume":"9","author":"AE Roser","year":"2017","unstructured":"Roser, A. E. et al. Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson\u2019s Disease and Amyotrophic Lateral Sclerosis. Front Aging Neurosci. 9, 94 (2017).","journal-title":"Front Aging Neurosci."},{"key":"40632_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.pharmthera.2013.10.009","volume":"141","author":"OP Keifer Jr.","year":"2014","unstructured":"Keifer, O. P. Jr. et al. Gene and protein therapies utilizing VEGF for ALS. Pharmacol Ther. 141, 261\u201371 (2014).","journal-title":"Pharmacol Ther."},{"key":"40632_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-018-0763-x","volume":"37","author":"R Huang","year":"2018","unstructured":"Huang, R. & Rofstad, E. K. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J Exp Clin Cancer Res. 37, 92 (2018).","journal-title":"J Exp Clin Cancer Res."},{"key":"40632_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ana.22611","volume":"70","author":"MA van Es","year":"2011","unstructured":"van Es, M. A. et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol. 70, 964\u201373 (2011).","journal-title":"Ann Neurol."},{"key":"40632_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2967\/jnumed.116.182824","volume":"58","author":"J Notni","year":"2017","unstructured":"Notni, J. et al. In Vivo PET Imaging of the Cancer Integrin \u03b1v\u03b26 Using 68Ga-Labeled Cyclic RGD Nonapeptides. J Nucl Med. 58, 671\u2013677 (2017).","journal-title":"J Nucl Med."},{"key":"40632_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1385\/NMM:7:3:207","volume":"7","author":"P Giraudon","year":"2005","unstructured":"Giraudon, P. et al. T-cells in neuronal injury and repair: semaphorins and related T-cell signals. Neuromolecular Med. 7, 207\u201316 (2005).","journal-title":"Neuromolecular Med."},{"key":"40632_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jneuroim.2017.01.008","volume":"305","author":"S Jacob","year":"2017","unstructured":"Jacob, S. et al. Assessment of plasma biomarkers for their association with Multiple Sclerosis progression. J Neuroimmunol. 305, 5\u20138 (2017).","journal-title":"J Neuroimmunol."},{"key":"40632_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum, J. M. et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 169, 13\u201321 (1999).","journal-title":"J Neurol Sci."},{"key":"40632_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/cells1030313","volume":"1","author":"H Ramachandran","year":"2012","unstructured":"Ramachandran, H. et al. Optimal Thawing of Cryopreserved Peripheral Blood Mononuclear Cells for Use in High-Throughput Human Immune Monitoring Studies. Cells. 1, 313\u201324 (2012).","journal-title":"Cells."},{"key":"40632_CR38","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nmeth.1714","volume":"8","author":"L Ting","year":"2011","unstructured":"Ting, L. et al. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat Methods. 8, 937\u20134020 (2011).","journal-title":"Nat Methods."}],"updated-by":[{"DOI":"10.1038\/s41598-020-74974-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40632-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40632-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40632-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:42:28Z","timestamp":1671262948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40632-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40632"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40632-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-74974-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"7 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Proteome Sciences employees receive revenues from manufacture and sale of TMT reagents. The other authors have no declarations of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4478"}}